Jefferies analyst Kelly Shi in a Sunday note to investors said that both data drops for Revolution Medicines’ experimental RAS inhibitors are positive for the two promising assets in pancreatic ductal adenocarcinoma, which could be “synergistic” in the first-line setting based on preclinical combination data.
